← All stocks

Lexeo Therapeutics, Inc.

LXEO Net selling
CIK 0001907108 #3249 in the set updated 17 Sep 2026
Bought (1 mo)
$0.00
out of their own pocket, the only kind of buying there is
Sold (1 mo)
$43.23K
$0.00 on a plan · $0.00 straight out of an exercise
Sold at will
$43.23K
3 of 3 sales
Net
−$43.23K
−$43.23K against sales at will

By person

9 insiders · 3 transactions
2.9×

R. Nolan Townsend holds only 2.9 times base salary in stock. $1.86M of shares against $632.70K in salary for 2025.

Salary from the company's own proxy. The shares are what R. Nolan Townsend last reported holding, valued at $4.96, the price Common Stock was last bought or sold at on the open market here, on 18 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Tamayo Louis Edward
Chief Financial Officer
$20.20K (1)
−$20.20K
92,907
$460.55K
Townsend Richard Nolan
Chief Executive Officer
$16.56K (1)
−$16.56K
374,472
$1.86M
+206.2%
Otero Jose Manuel
Chief Operating Officer
$6.46K (1)
−$6.46K
136,178
$675.05K
+335.8%
Bhalla Narinder Pal
Chief Medical Officer
82,194
$407.44K
Adler Eric
Chief Medical Officer
72,646
$360.11K
+170.3%
Robertson Jenny
Chief Legal Officer
68,381
$338.97K
+187.9%
See Tai Sandi
Chief Development Officer
65,476
$324.57K
+293.8%
Rasbach Kyle
Chief Financial Officer
40,875
$202.62K
CHOLMONDELEY PAULA H
Director
30,627
$151.82K
+96.0%

No percentages here. This company's share count has moved by a factor of 2.5 over the window, from 33,065,947 to 82,046,255 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Nothing of that kind in this period.

What was left out

Form 4 filings counted 3
Amendments (4/A) skipped 0
Filings about a different issuer 0
Unreadable filings 0
Joint filings 0
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 0
Sales at will 3
Transactions with no price 0
Shares from compensation/vesting 0
History held since 9 Nov 2023